Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine

MLA

Tina C. Albershardt, et al. “Therapeutic Efficacy of PD1/PDL1 Blockade in B16 Melanoma Is Greatly Enhanced by Immunization with Dendritic Cell-Targeting Lentiviral Vector and Protein Vaccine.” Vaccine, vol. 38, Apr. 2020, pp. 3369–77. EBSCOhost, https://doi.org/10.1016/j.vaccine.2020.02.034.

APA

Tina C. Albershardt, Rebecca S. Reeves, Peter Berglund, Patrick A. Flynn, David J. Campbell, Andrea J. Parsons, & Jan ter Meulen. (2020). Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine. Vaccine, 38, 3369–3377. https://doi.org/10.1016/j.vaccine.2020.02.034

Chicago

Tina C. Albershardt, Rebecca S. Reeves, Peter Berglund, Patrick A. Flynn, David J. Campbell, Andrea J. Parsons, and Jan ter Meulen. 2020. “Therapeutic Efficacy of PD1/PDL1 Blockade in B16 Melanoma Is Greatly Enhanced by Immunization with Dendritic Cell-Targeting Lentiviral Vector and Protein Vaccine.” Vaccine 38 (April): 3369–77. doi:10.1016/j.vaccine.2020.02.034.